Is Macrobid (nitrofurantoin) safe to use during pregnancy for a urinary tract infection (UTI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 16, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Macrobid (Nitrofurantoin) Use in Pregnancy

Nitrofurantoin is safe and recommended as a first-line treatment for urinary tract infections during pregnancy, including the first trimester, with the exception of avoiding use at term (near delivery) due to theoretical risk of neonatal hemolysis. 1, 2

First-Line Treatment Recommendations

Nitrofurantoin is explicitly recommended by multiple international guidelines as first-line therapy for UTI in pregnancy:

  • The European Association of Urology (2024) lists nitrofurantoin macrocrystals 50-100 mg four times daily for 5 days or nitrofurantoin monohydrate/macrocrystals 100 mg twice daily for 5 days as primary treatment options 1
  • Treatment duration should be 4-7 days for asymptomatic bacteriuria or 5-7 days for symptomatic UTI, with 7-14 days recommended for more severe infections 1, 2
  • A urine culture must always be obtained before initiating treatment to guide antibiotic selection and confirm diagnosis 2

Safety Profile Across Trimesters

First and Second Trimesters:

  • Multiple meta-analyses demonstrate no significant increased risk of major congenital malformations with first-trimester exposure 3, 4
  • Cohort studies of 9,275 exposed infants showed no increased risk (RR 1.01,95% CI 0.81-1.26) 4
  • A retrospective analysis of 91 pregnancies treated with nitrofurantoin found no drug-related abnormal events, with outcomes comparable to the general U.S. population 5
  • Nitrofurantoin has been safely used for over 35 years in pregnancy with a continuing safety record 6

Third Trimester - Important Caveat:

  • Nitrofurantoin should be avoided at term (near delivery) due to theoretical risk of hemolytic anemia in neonates with G6PD deficiency 2
  • For third-trimester UTIs, cephalexin 500 mg four times daily for 7-14 days is the preferred alternative 2

Critical Clinical Context

Why treatment is essential in pregnancy:

  • Untreated bacteriuria increases pyelonephritis risk 20-30 fold (from 1-4% with treatment to 20-35% without treatment) 1, 2
  • Treatment reduces premature delivery and low birth weight infants 1, 2
  • Pregnancy is the one clinical scenario where even asymptomatic bacteriuria must always be treated 1, 2
  • Screening should ideally occur at 12-16 weeks gestation 2

Alternative Agents When Nitrofurantoin Cannot Be Used

If nitrofurantoin is contraindicated or at term:

  • Cephalexin (cephalosporins) are excellent alternatives with proven safety profiles 1, 2
  • Fosfomycin trometamol 3g single dose is acceptable for uncomplicated lower UTIs 1, 2
  • Amoxicillin-clavulanate if pathogen is susceptible 2

Agents to avoid:

  • Trimethoprim and trimethoprim-sulfamethoxazole should not be used in the first trimester due to teratogenic effects and are contraindicated in the last trimester 1, 2
  • Fluoroquinolones should be avoided throughout pregnancy due to potential cartilage development effects 2

Common Pitfalls to Avoid

  • Do not use nitrofurantoin for suspected pyelonephritis, as it does not achieve therapeutic blood concentrations; use cephalosporins or other agents that achieve adequate systemic levels 2
  • Do not perform repeated surveillance urine testing or treat asymptomatic bacteriuria multiple times after initial treatment, as this fosters antimicrobial resistance 2
  • Do not delay treatment while awaiting culture results in symptomatic patients, as this increases risk of progression to pyelonephritis 2
  • Obtain follow-up urine culture 1-2 weeks after completing treatment to confirm cure 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of UTI During Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Exposure to nitrofurantoin during early pregnancy and congenital malformations: a systematic review and meta-analysis.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2015

Research

Nitrofurantoin: an update.

Obstetrical & gynecological survey, 1989

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.